Skip to main content

Cardlytics Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders' Equity (Unaudited)

Nine Months Ended September 30, 2024:

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Income (Loss) · AccumulatedDeficit · Total
Common Stock
Shares · Amount
Balance – December 31, 202339,728$9$1,243,594$2,467$(1,111,272)$134,798
Exercise of common stock options3—5——5
Stock-based compensation——35,396——35,396
Settlement of restricted stock2,869—————
Issuance of common stock, net of issuance costs3,592—27,451——27,451
Issuance of common stock, net of issuance costs - ATM Offering Program (as defined below)3,908—48,151——48,151
Issuance of common stock pursuant to the 2018 ESPP (as defined below)242—1,461——1,461
Termination of capped calls related to 2020 Convertible Senior Notes——115——115
Other comprehensive loss———(3,965)—(3,965)
Net Loss————(173,715)(173,715)
Balance – September 30, 202450,342$9$1,356,173$(1,498)$(1,284,987)$69,697

Three Months Ended September 30, 2024:

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Income · AccumulatedDeficit · Total
Common Stock
Shares · Amount
Balance – June 30, 202449,402$9$1,346,876$2,953$(1,139,805)$210,033
Stock-based compensation——9,297——9,297
Settlement of restricted stock940—————
Other comprehensive loss———(4,451)—(4,451)
Net Loss————(145,182)(145,182)
Balance – September 30, 202450,342$9$1,356,173$(1,498)$(1,284,987)$69,697

Nine Months Ended September 30, 2023:

AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome · AccumulatedDeficit · Total
Common Stock
Shares · Amount
Balance – December 31, 202233,477$9$1,182,568$5,598$(976,570)$211,605
Exercise of common stock options10—54——54
Stock-based compensation——31,561——31,561
Settlement of restricted stock2,004—————
Issuance of common stock2,755—15,171——15,171
Issuance of common stock pursuant to the 2018 ESPP (as defined below)282—1,104——1,104
Other comprehensive loss———(294)—(294)
Net Loss————(33,866)(33,866)
Balance – September 30, 202338,528$9$1,230,458$5,304$(1,010,436)$225,335

Three Months Ended September 30, 2023:

AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome · AccumulatedDeficit · Total
Common Stock
Shares · Amount
Balance – June 30, 202337,088$9$1,219,530$3,043$(986,470)$236,112
Exercise of common stock options6—44——44
Stock-based compensation——10,884——10,884
Settlement of restricted stock1,434—————
Other comprehensive income———2,261—2,261
Net Loss————(23,966)(23,966)
Balance – September 30, 202338,528$9$1,230,458$5,304$(1,010,436)$225,335
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.